

Product Datasheet

ABBV-744 (orb525750)

Description

ABBV-744 is a BDII-selective BET bromodomain inhibitor that is being investigated to treat AML and metastatic castration-resistant prostate cancer. ABBV-744, a highly potent and selective inhibitor of the BD2 domain of BET family proteins with drug-like properties. In contrast to the broad range of cell growth inhibition induced by DbBi, the antiproliferative activity of ABBV-744 was largely, but not exclusively, restricted to cell lines of acute myeloid leukaemia and prostate cancer that expressed the full-length androgen receptor (AR). ABBV-744 retained robust activity in prostate cancer xenografts, and showed fewer platelet and gastrointestinal toxicities than the DbBi ABBV-07514. Analyses of RNA expression and chromatin immunoprecipitation followed by sequencing revealed that ABBV-744 displaced BRD4 from AR-containing super-enhancers and inhibited AR-dependent transcription, with less impact on global transcription compared with ABBV-075. These results underscore the potential value of selectively targeting the BD2 domain of BET family proteins for cancer therapy.

Note

For research use only

Formula

$C_{28}H_{30}FN_3O_4$

MW

491.56

CAS Number

[2138861-99-9]

SMILES

O=C(C(N1)=CC(C(C2=CC(C(C)(O)C)=CC=C2OC3=C(C)C=C(F)C=C3C)=CN4C)=C1C4=O)NCC

Expiration Date

12 months from date of receipt.

Biorbyt Ltd.

7 Signet Court, Swann's Road,
Cambridge, CB5 8LA, United Kingdom
Email: info@biorbyt.com, support@biorbyt.com
Phone: [+44 \(0\) 1223 859-353](tel:+44(0)1223859353) | Fax: [+1 \(415\) 651-8558](tel:+1(415)6518558)

Biorbyt LLC.

68 TW Alexander Drive,
Durham, NC, 27713, United States
Email: info@biorbyt.com, support@biorbyt.com
Phone: [+1 \(415\) 906-5211](tel:+1(415)9065211) | Fax: [+1 \(415\) 651-8558](tel:+1(415)6518558)